Brief: Cognition Therapeutics Completes Enrollment In Phase 2 Shine Study Of CT1812 In Mild-To-Moderate Alzheimer’S Disease
07/11/2023 12:38
Nov 7 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2
SHINE
STUDY OF CT1812 IN MILD-TO-MODERATE ALZHEIMER’S DISEASE
* COGNITION THERAPEUTICS INC - TOP-LINE RESULTS EXPECTED MID
2024
Source text for Eikon: ID:nGNX7jKCjn
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB